Similar articles for PMID: 6433688

Year	Number of Results
1946	1
1956	1
1962	1
1967	1
1968	1
1970	1
1971	1
1972	4
1973	2
1974	4
1975	9
1976	10
1977	4
1978	10
1979	14
1980	15
1981	30
1982	26
1983	26
1984	54
1985	38
1986	42
1987	29
1988	28
1989	23
1990	20
1991	16
1992	10
1993	7
1994	6
1995	3
1996	5
1997	5
1998	2
1999	1
2000	1
2001	1
2002	1
2003	3
2005	1
2006	2
2009	1
2010	1
2011	3
2014	1
2015	1
2016	2
2018	1
2019	4
2020	3
2023	1
2024	0

1

Clinical efficacy and electrophysiologic effects of intravenous and oral encainide in patients with accessory atrioventricular pathways and supraventricular arrhythmias.

Abdollah H, Brugada P, Green M, Wehr M, Wellens HJ. Abdollah H, et al. Am J Cardiol. 1984 Sep 1;54(6):544-9. doi: 10.1016/0002-9149(84)90245-5. Am J Cardiol. 1984. PMID: 6433688

2

Electrophysiologic and clinical effects of intravenous and oral encainide in accessory atrioventricular pathway.

Kunze KP, Kuck KH, Schlüter M, Kuch B, Bleifeld W. Kunze KP, et al. Am J Cardiol. 1984 Aug 1;54(3):323-9. doi: 10.1016/0002-9149(84)90191-7. Am J Cardiol. 1984. PMID: 6431796

3

Clinical efficacy and electrophysiologic effects of encainide in patients with Wolff-Parkinson-White syndrome.

Prystowsky EN, Klein GJ, Rinkenberger RL, Heger JJ, Naccarelli GV, Zipes DP. Prystowsky EN, et al. Circulation. 1984 Feb;69(2):278-87. doi: 10.1161/01.cir.69.2.278. Circulation. 1984. PMID: 6418407

4

Electrophysiology in assessing supraventricular arrhythmias: value of programmed stimulation in predicting and understanding efficacy of encainide.

Wellens HJ, Brugada P. Wellens HJ, et al. Am J Cardiol. 1986 Aug 29;58(5):37C-40C. doi: 10.1016/0002-9149(86)90102-5. Am J Cardiol. 1986. PMID: 3092617

5

Suppression of incessant supraventricular tachycardia by intravenous and oral encainide.

Brugada P, Abdollah H, Wellens HJ. Brugada P, et al. J Am Coll Cardiol. 1984 Dec;4(6):1255-60. doi: 10.1016/s0735-1097(84)80146-1. J Am Coll Cardiol. 1984. PMID: 6438205 Free article.

6

Electrophysiologic and clinical effects of intravenous and oral encainide in patients with Wolff-Parkinson-White syndrome and paroxysmal atrial fibrillation.

Chimienti M, Moizi M, Salerno JA, Klersy C, Guasti L, Previtali M, Marangoni E, Montemartini C, Bobba P. Chimienti M, et al. Eur Heart J. 1987 Mar;8(3):282-90. doi: 10.1093/oxfordjournals.eurheartj.a062271. Eur Heart J. 1987. PMID: 3107987

7

Electrophysiologic and antiarrhythmic effects of oral encainide in patients with atrioventricular nodal reentry or nodoventricular reentry.

Miles WM, Chang MS, Heger JJ, Rinkenberger RL, Zipes DP, Prystowsky EN. Miles WM, et al. Am Heart J. 1987 Jul;114(1 Pt 1):26-33. doi: 10.1016/0002-8703(87)90302-4. Am Heart J. 1987. PMID: 3111237

8

Usefulness of programmed stimulation in predicting efficacy of propafenone in long-term antiarrhythmic therapy for paroxysmal supraventricular tachycardia.

Manz M, Steinbeck G, Lüderitz B. Manz M, et al. Am J Cardiol. 1985 Oct 1;56(10):593-7. doi: 10.1016/0002-9149(85)91017-3. Am J Cardiol. 1985. PMID: 4050693

9

Encainide for treatment of atrioventricular reciprocating tachycardia in the Wolff-Parkinson-White syndrome.

Miles WM, Zipes DP, Rinkenberger RL, Markel ML, Prystowsky EN, Dougherty AH, Heger JJ, Naccarelli GV. Miles WM, et al. Am J Cardiol. 1988 Dec 20;62(19):20L-25L. doi: 10.1016/0002-9149(88)90011-2. Am J Cardiol. 1988. PMID: 3144163

10

Encainide for treatment of supraventricular tachycardias associated with the Wolff-Parkinson-White syndrome.

Markel ML, Prystowsky EN, Heger JJ, Miles WM, Fineberg N, Zipes DP. Markel ML, et al. Am J Cardiol. 1986 Aug 29;58(5):41C-48C. doi: 10.1016/0002-9149(86)90103-7. Am J Cardiol. 1986. PMID: 3092619

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

474 results

Results by year